On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for oncology research applications.
The partnership aims to use Qiagen’s global reach and automation expertise with ID Solutions’ assay development and manufacturing capabilities to strengthen Qiagen’s position in oncology research.
A scientist in a lab coat using the latest medical equipment for nucleic acid purification.
Under the terms of the agreement, ID Solutions will produce and supply dPCR assays specifically for non-clinical research use on Qiagen’s QIAcuity platforms. These assays are designed to identify multiple mutations simultaneously in cell-free DNA extracted from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue samples. Qiagen will initially market these kits in Europe, with plans for future expansion into other regions.
The newly added assays will complement Qiagen’s current PanCancer Kits for detecting various hallmark mutations in DNA from diverse sample types, as well as over 200 locked nucleic acid (LNA) mutation assays. For customers, this collaboration translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, which promise results in less than a day. Qiagen (NYSE:QGEN) provides sample-to-insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
While we acknowledge the potential of QGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QGEN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
